PDLIM2 and cancer: This is in sharp contrast to the Food and Drug Administration (FDA)-approved epigenetic drugs, which can restore PDLIM2 expression in cancer cells with PDLIM2 epigenetic repression (Sun et al., 2019; Guo and Qu, 2021; Qu et al., 2010a; Qu et al., 2010b; Sun et al., 2015; Yan et al., 2009b; Vanoirbeek et al., 2014).